A Phase II Study of Umbilical Cord Blood Transplantation

• Sponsor: Tufts Medical Center (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00676806
• Collaborator: (none)
• Enrollment: 7
• Location: 1
• Arms: 2
• Duration (Months): 108
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This study is designed to determine whether Umbilical Cord Transplantation (UCB) can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.

Condition or Disease	Intervention/Treatment	Phase
Leukemia; Lymphoma; Multiple Myeloma; Aplastic Anemia	Biological: Umbilical Cord Blood After Myeloablative Conditioning; Biological: Umbilical Cord Blood After Reduced-Intensity Conditioning	Phase 2

Detailed Description

Allogeneic stem cell transplantation (SCT) following myeloablative and non-myeloablative conditioning therapy has proven curative treatment for a number of inherited and acquired hematologic disorders. The success of allogeneic transplantation is largely determined by compatibility between donor and recipient, which predicts the risk of fatal graft-versus-host disease (GVHD). Unfortunately, less than one third of patients needing an allogeneic transplant have an available compatible donor in their family. Registries have been established to match patients with compatible volunteer (unrelated) donors, but many patients, and in particular minority patients, still lack stem cell donors.

Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells, which is readily available from the placenta following childbirth. Blood banks have been established in the United States and abroad to collect, process and store UCB for use in allogeneic transplantation. To date, more than 2000 UCB transplants have been performed in adults and children around the world.

Rationale for use of Umbilical Cord Blood in Transplantation

UCB has a number of proven and theoretical advantages as an alternative source of hematopoietic stem cells for transplantation:

1. Placental or umbilical cord blood is an abundantly available source of stem cells, which is currently discarded and can be harvested at no risk to the mother or infant.

2. Important infectious agents, particularly CMV, are much less common in the newborn than adults, and are less likely to contaminate UCB collections.

3. UCB collections, typed, cryopreserved and banked, are available on demand, eliminating delays and uncertainties that now complicate marrow collection from unrelated donors. At present, UCB can be delivered for infusion within days of the initiation of a search. This compares with a median of 3 months from search to delivery of stem cells through the registries of volunteer adult donors.

4. The intensity of graft-versus-host reactivity of fetal lymphocytes appears to be less than that of adult cells and consequently fetal lymphocytes are more tolerant of HLA incompatibility. Published studies have shown that transplantation of UCB matched at 4-5/6 antigens results in a comparable incidence of GVHD to transplantation of unrelated stem cells fully matched at 6/6 antigens.

5. Frozen UCB can be easily shipped, stored at the treating institution, and thawed for use when needed, compared to freshly donated stem cells which have a limited shelf-life of one day or less, necessitating coordination between harvesting surgeons, transportation, and transplantation teams.

This research study has been designed for people who have been diagnosed with a blood tumor, which has not responded to treatment or has recurred, a bone marrow failure state such as aplastic anemia, or one of certain inherited metabolic disorders; and whose doctor feels the best treatment is an allogeneic stem cell transplant (alloSCT) but a related or unrelated adult donor is not available. Instead, a single unit of umbilical cord blood (UCB) will be used as the source of the subject's immune system. This study is designed to determine whether a single unit of UCB can be substituted for adult bone marrow cells in the standard stem cell transplant regimens used at this hospital for subjects who do not have stem cell donors.

Study Design

• Study Type: Interventional
• Actual Enrollment: 7 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning
• Study Start Date: Jul 1, 2005
• Actual Primary Completion Date: Jul 1, 2013
• Actual Study Completion Date: Jul 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Myeloablative conditioning Umbilical cord blood for hematopoietic rescue following myeloablative conditioning	Biological: Umbilical Cord Blood After Myeloablative Conditioning; cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.; Other Names: Cytoxan TBI Fludara Busulfex UCBT
Experimental: Reduced intensity conditioning Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning	Biological: Umbilical Cord Blood After Reduced-Intensity Conditioning; Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.; Other Names: Psoralen Cytoxan Nypent TBI UCBT

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Neutrophil Engraftment [+45 and 90 days]

   Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning

Secondary Outcome Measures

1. Proportion of Subjects With Platelet Engraftment [+45, 90, and 180 days]

   Proportion of patients engrafting by days +45, +90, and +180.

2. Incidence of Acute GVHD [Day +100]

3. Infectious Complications in UCB Recipients. [Day +100]

4. Incidence of Chronic GVHD [After Day +100]

5. Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation [+180 days]

   Composite endpoint of GVH or infection. Too few events to compare between arms.

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

Patients meeting eligibility criteria for unrelated allogeneic stem cell transplantation may be considered for participation on this clinical trial if and only if they meet each of the following criteria:

• Patients must have one of the following diagnoses

• Relapsed or refractory hematologic malignancy, or

• High risk hematologic malignancy in first remission, or

• Refractory acquired marrow failure state, or

• Inherited disorder of metabolism or marrow failure state without alternative curative therapy.

• Patients must not have a 6/6 or 5/6 HLA-matched related donor.

• Patients must not have a HLA-A, -B and -DRB1 high resolution matched unrelated donor following registry search, or cannot (in the opinion of the treating physician) wait the median 3 months to receive a MUD unit.

• Patients must demonstrate an ability to understand and willingness to sign the informed consent document

Patients considered for myeloablative conditioning must satisfy the following additional criteria:

• Patients must be up to age 55 (inclusive)

• Patients must have serum direct bilirubin ≤ 2.0 mg/dl and transaminases ≤ 2x institution upper limit of normal

• Patients must have serum creatinine ≤ 2 mg/dl with creatinine clearance ≥ 60 ml/min (either calculated or measured).

• Patients must have MUGA scan or echocardiogram normal for the institution, but not less than 45% left ventricular ejection fraction and no clinical evidence of cardiac dysfunction.

• Patients must have an ECOG performance status of 0 or 1 (see Appendix C).

• Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 > 50% of predicted.

Patients considered for reduced-intensity conditioning must satisfy the following additional criteria:

• Patients must not be candidates for myeloablative conditioning due to any one of the following: Prior myeloablative stem cell transplantation, Age > 50, Co morbid illness

• In opinion of treating physician, unable to comply with or withstand rigors of myeloablative conditioning

• Patients with leukemia must have circulating and bone marrow blast counts < 5%, all other patients must have chemotherapy responsive disease

• Patients must be between the ages of 18 and 70 (inclusive)

• Patients must have serum direct bilirubin ≤ 2.0 mg/dL and transaminases ≤ 3x institution upper limit of normal

• Patients must have creatinine clearance ≥ 30 ml/min (either calculated or measured).

• Patients must have MUGA scan or echocardiogram documenting left ventricular ejection fraction of no less than 35% and no clinical evidence of cardiac dysfunction.

Patients must have an ECOG performance status of 0 or 1 (see Appendix C).

Patients must have adequate pulmonary function when corrected for hemoglobin and alveolar volume as evidenced by a diffusion capacity and FEV1 ≥ 40% of predicted.

Exclusion Criteria:

Patients are ineligible for participation on this trial if they meet any of the following criteria:

• Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, uncontrolled hypertension or congestive heart failure are ineligible.

• Patients with unstable angina are not eligible.

• Pregnant or lactating women are ineligible.

• Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.

• Patients with uncontrolled infection are ineligible.

• Patients who are HIV positive or have evidence of chronic viral hepatitis are ineligible.

• Patients unable to comply with requirements for compliance with therapeutic plan and/or scheduled evaluations

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tufts Medical Center	Boston	Massachusetts	United States	02111

Sponsors and Collaborators

• Tufts Medical Center

Investigators

• Principal Investigator: Andreas Klein, MD, Tufts Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Tufts Medical Center
• ClinicalTrials.gov Identifier: NCT00676806
• Other Study ID Numbers: UCBT001
• First Posted: May 13, 2008
• Last Update Posted: Jun 1, 2017
• Last Verified: May 1, 2017

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by Tufts Medical Center: Umbilical cord blood transplantation; full ablation conditioning; reduced intensity conditioning
• Additional relevant MeSH terms: Multiple Myeloma; Anemia, Aplastic; Cyclophosphamide

Study Results

Participant Flow

Pre-assignment Detail	One subject signed consent but did not receive a transplant, so was dropped from the study and was not assigned to either arm.

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
Period Title: Overall Study
STARTED	3	3
COMPLETED	3	3
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning	Total
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.	Total of all reporting groups
Overall Participants	3	3	6
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	3 100%	3 100%	6 100%
>=65 years	0 0%	0 0%	0 0%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	43 (8.1)	62.6 (2.3)	52.8 (12)
Sex: Female, Male (Count of Participants)
Female	1 33.3%	2 66.7%	3 50%
Male	2 66.7%	1 33.3%	3 50%
Region of Enrollment (participants) [Number]
United States	3 100%	3 100%	6 100%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Neutrophil Engraftment
Description	Number of participants with neutrophil engraftment receiving umbilical cord blood for hematopoietic rescue following myeloablative or non-myeloablative conditioning
Time Frame	+45 and 90 days

Outcome Measure Data

Analysis Population Description

Only 2 subjects were evaluable from each group at the +45 day mark. The same number were evaluable at the +90 day mark.

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning. 2/2 evaluable subjects engrafted at +45 and +90 days.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning 1/2 evaluable subjects engrafted at +45 and +90 days.
Measure Participants	2	2
Number [participants]	2 66.7%	1 33.3%

2. Secondary Outcome

Title	Proportion of Subjects With Platelet Engraftment
Description	Proportion of patients engrafting by days +45, +90, and +180.
Time Frame	+45, 90, and 180 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Measure Participants	2	2
Platelet Engraftment +45 days	0 0%	2 66.7%
Platelet Engraftment +90 days	0 0%	0 0%
Platelet Engraftment +180 days	1 33.3%	0 0%

3. Secondary Outcome

Title	Incidence of Acute GVHD
Time Frame	Day +100

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Measure Participants	3	3
Number [participants]	1 33.3%	0 0%

4. Secondary Outcome

Title	Infectious Complications in UCB Recipients.
Time Frame	Day +100

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Measure Participants	3	3
Number [participants]	3 100%	3 100%

5. Secondary Outcome

Title	Incidence of Chronic GVHD
Time Frame	After Day +100

Outcome Measure Data

Analysis Population Description

No subject receiving reduced intensity conditioning was evaluable for the event of chronic GVHD (0/3 subjects survived to day +100)

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
Measure Participants	2	0
Number [participants]	1 33.3%

6. Secondary Outcome

Title	Compare Rates of Complications Between Patients Receiving Ablative vs. Non-myeloablative Conditioning Prior to UCB Transplantation
Description	Composite endpoint of GVH or infection. Too few events to compare between arms.
Time Frame	+180 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Myeloablative Conditioning	Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning. 2/2 evaluable subjects engrafted at +45 and +90 days. 3 evaluable subjects for toxicity.	Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning 1/2 evaluable subjects engrafted at +45 and +90 days. 3 evaluable subjects for toxicity.
Measure Participants	3	3
Number [events]	5	3

Adverse Events

Arm/Group Title	Myeloablative Conditioning		Reduced Intensity Conditioning
Arm/Group Description	Patients receiving umbilical cord blood for hematopoietic rescue following myeloablative conditioning Umbilical Cord Blood Transplantation After Myeloablative Conditioning: Fully-myeloablative Conditioning Regimen: cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.		Patients receiving umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning: Reduced Intensity Conditioning Regimen: Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
All Cause Mortality
	Myeloablative Conditioning		Reduced Intensity Conditioning
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Myeloablative Conditioning		Reduced Intensity Conditioning
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/3 (100%)		3/3 (100%)
Blood and lymphatic system disorders
Febrile Neutropenia	3/3 (100%)	3	0/3 (0%)	0
Bone marrow hypocellular	0/3 (0%)	0	1/3 (33.3%)	1
Cardiac disorders
Atrial fibrillation	0/3 (0%)	0	1/3 (33.3%)	1
Gastrointestinal disorders
Typhlitis	1/3 (33.3%)	1	2/3 (66.7%)	2
Immune system disorders
Gastrointestinal GVHD	2/3 (66.7%)	2	0/3 (0%)	0
Infections and infestations
Sepsis	3/3 (100%)	3	2/3 (66.7%)	2
Lung Infection	2/3 (66.7%)	2	1/3 (33.3%)	1
Renal and urinary disorders
Renal Failure	1/3 (33.3%)	1	0/3 (0%)	0
Respiratory, thoracic and mediastinal disorders
Respiratory Failure	1/3 (33.3%)	1	2/3 (66.7%)	2
Pulmonary Hemorrhage	1/3 (33.3%)	1	0/3 (0%)	0
Vascular disorders
Thrombotic microangiopathy	0/3 (0%)	0	1/3 (33.3%)	1
Thromboembolic event	0/3 (0%)	0	1/3 (33.3%)	1
Other (Not Including Serious) Adverse Events
	Myeloablative Conditioning		Reduced Intensity Conditioning
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/3 (33.3%)		0/3 (0%)
Psychiatric disorders
Confusion	1/3 (33.3%)	1	0/3 (0%)	0
Skin and subcutaneous tissue disorders
Skin Nodules	1/3 (33.3%)	1	0/3 (0%)	0

Limitations/Caveats

Early termination leading to small numbers of subjects analyzed.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.